Compare Cronos Group Inc (CRON) vs Docusign Inc (DOCU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cronos Group Inc vs Docusign Inc — how do they compare? Cronos Group Inc trades at $3.23 (market cap $1.18B), while Docusign Inc trades at $71.08 (market cap $13.35B). The key difference: Docusign Inc is far larger — about 11.3× Cronos Group Inc's market cap, and Docusign Inc is trading nearer its 52-week high, Cronos Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cronos Group Inc for 22 Days and Docusign Inc for 71 Days on average.
| CRON | DOCU | |
|---|---|---|
Market Cap | $1.18B | $13.35B |
Volume | 968,037 | 3,158,858 |
Sector | Health | Technology |
52-Week High | $3.55 | $73.14 |
52-Week Low | $2.30 | $41.75 |
Typical Hold Time | 22 Days | 71 Days |
Enterprise Value | $387.62M | $12.76B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRON trades at $3.22, down 0.62% on the day, with a bearish technical signal from moving averages. The company reported strong Q2 2026 results, beating earnings estimates with 58% YoY revenue growth, and maintains a robust balance sheet with $827 million in cash and no debt. Recent investor day highlighted expansion in Canada and international markets.
Outlook is mixed; profitability improved with net income margin turning positive in 2026 forecasts, but high EV/EBITDA of 43 suggests premium valuation. Risks include execution of growth plans and cannabis sector volatility. Analyst consensus is cautious with 60% hold ratings.
DOCU trades at $71.43, up 3.67% on the day, with a bullish technical signal and strong earnings beats in recent quarters. Revenue grew to $2.98B in 2025, with net income surging to $1.07B, though cash flow turned negative. The stock is supported by AI-driven IAM adoption and leadership in signing workflow software, as noted in recent news.
Outlook is mixed: growth from AI and market position offers upside, but high valuation (P/E 43.55), insider selling, and slowing revenue growth pose risks. Analyst consensus is cautious with a $68.75 target below current price, suggesting limited near-term gains amid competitive and execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cronos Group Inc
Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.
Read more on CRON →About Docusign Inc
DocuSign offers the Agreement Cloud, a broad cloud-based software suite that enables users to automate the agreement process and provide legally binding e-signatures from nearly any device. The company was founded in 2003 and completed its IPO in May 2018.
Read more on DOCU →
